and enteral nutrition, 781, 782, 785, 786, 787

laboratory tests for, 17–20t

and metabolic disturbances, 611

PN and, 801t

Electronic cigarettes, electronic nicotine delivery systems (ENDS), 1904, 1922

Electronic medical record (EMR), 3t

Electronic medication administration record (eMAR), 3

Electrophysiology

automaticity, 307

cardiac, 307–308

cellular, 307

conduction, 307–308

ELISA (see Enzyme-linked immunosorbent assays (ELISA))

ELITE (see Evaluation of Losartan in the Elderly (ELITE))

EM (see Erythema multiforme (EM))

eMAR (see Electronic medication administration record (eMAR))

Embolus, 174

Embryo transfer, 965

Emesis (see Vomiting)

EMLA (see Eutectic mixture of local anesthetics (EMLA))

E. moshkovskii, 1702

Emphysema, 409, 410

Empiric antibiotics, 661

Empiric broad-spectrum therapy, 369

Empiric therapy

in adults, 1377

for biliary infections, 1478

for hospital-acquired pneumonia, 1416–1417t

for secondary peritonitis, 1478

EMR (see Electronic medical record (EMR))

EN (see Enteral nutrition (EN))

Endocarditis, 1384–1403

culture-negative, 1401

enterococcal, 1396–1399

fungal, 1399–1400

gram-negative bacillary, 1400–1401

infective, 1385–1386

prophylactic therapy for, 1401–1403

prosthetic valve, 1391–1393

Staphylococcus aureus, 1393–1396

Streptococcus viridans, 1386–1391

Endocrine abnormalities, caused by uremia, 623

End-of-life care, 83–92

dyspnea treatment in, 89t

hospice care in, 83–88

palliative care in, 83–88

symptom management in, 88–92

Endometrial cancer

and antiestrogens, 1964t

and postmenopausal hormone therapy, 1031t, 1032

Endometriosis

abdominal hysterectomy for, 1020

bilateralsalpingo-oophorectomy for, 1020

clinical characteristics of, 1017–1019

conservative surgery for, 1020–1021

definition of, 1016

definitive surgery for, 1020

and depression, 1018–1019

diagnosis of, 1017

estrogen add-back therapy for, 1021

and infertility, 1019

management of, 1022

location of, 1017, 1018t

occurrence of, 1017

pathophysiology of, 1017

physical findings of, 1019

treatment, 1019–1022

Endoscopic retrograde cholangiopancreatography (ERCP), 1472

Endoscopic variceal ligation (EVL), 548–549

Endoscopy-negative reflux disease (ENRD), 502

Endothelial cell dysfunction, in pregnancy, 984–985

Endothelial function, 210f

Endothelin-1, biological effects of, 266t

Endothelins and HF, 266

ENDS (see Electronic cigarettes, electronic nicotine delivery systems (ENDS))

End-stage liver disease

ascites

alternative therapy, 545–546

diuretic therapy, 543–544

fluid and electrolyte balance, 542–543

goals of therapy, 542

pathogenesis of, 542

refractory, 544–545

cirrhosis

complications of, 540–542, 540f, 541t

pathogenesis of, 539–540

esophageal varices, treatment of, 546–551, 548t

hepatic encephalopathy, 551–552

pathogenesis, 552

treatment and general management, 552–554

End-stage lung disease, 464

End-stage renal disease (ESRD), 598, 652

clinicalsigns and symptoms, 606, 606–607t

hemodialysis

complications, 657–659

principles and transport processes, 652–655, 653f, 655t

vascular access, 655–657

peritoneal dialysis

access, 660–661

dialysis prescription, 661–663

principles and transport processes, 659–660, 660f

treatment, 607

Energy-dependent phase I (EDP-I), 48

Energy-dependent phase II (EDP-II), 48

The enhanced amplified M. tuberculosis direct test, 1426

ENRD (see Endoscopy-negative reflux disease (ENRD))

Enteral nutrition (EN)

administration regimen for, 775–776

for adults, 768–790

complications with, 782–785, 783–784t

g

a

s

tr

o

int

e

s

t

in

a

l,

7

8

5

me

c

h

a

nic

a

l,

7

8

2

me

t

a

b

o

lic

,

7

8

2

,

7

8

5

c

o

ntr

a

in

dic

a

t

io

n

s

t

o

,

7

7

0

in

c

r

it

ic

a

l

illn

e

s

s

,

7

7

6–

7

7

9

d

e

finit

io

n

o

f,

7

6

8

fo

r

dia

b

e

t

e

s

,

7

8

1

–

7

8

2

dia

r

r

h

e

a

a

n

d

,

7

8

8

–

7

9

0

e

le

c

tr

o

lyt

e

s

a

n

d

,

7

8

1

,

7

8

2

,

7

8

5

,

7

8

6

,

7

8

7

fa

t

in

,

7

7

9

fe

e

din

g

tub

e

o

c

c

lu

s

io

n

a

n

d

,

7

8

7

–

7

8

8

fluid

s

a

n

d

,

7

7

6

fo

r

mula

s

fo

r

,

7

7

1

–

7

7

5

,

7

7

2

t

b

o

lu

s

d

e

liv

e

r

y

o

f,

7

7

5

c

o

nt

inu

o

u

s

in

fu

s

io

n

o

f,

7

7

5

c

y

c

lic

in

fu

s

io

n

o

f,

7

7

5

p. 2

3

3

7

p. 2

3

3

8

immun

e

-

mo

dula

t

in

g

,

7

7

9

int

e

r

mitt

e

nt

in

fu

s

io

n

o

f,

7

7

5

o

lig

o

me

r

ic

,

7

7

1

,

7

7

3

p

o

lyme

r

ic

,

7

7

1

s

p

e

c

ia

liz

e

d

,

7

7

3

–

7

7

5

g

lu

c

o

s

e

a

n

d

,

7

8

1

–

7

8

2

fo

r

h

e

p

a

t

ic

fa

ilur

e

,

7

7

7

hyp

e

r

g

ly

c

e

mia

w

ith

,

7

8

1

fo

r

in

fa

nt

s

,

2

1

4

3

–

2

1

5

2

b

r

e

a

s

t

fe

e

din

g

,

2

1

4

3

–

2

1

4

5

,

2

1

4

4

t

a

n

d

c

a

rb

o

hy

dr

a

t

e

a

b

s

o

rp

t

io

n

,

2

1

4

7

a

n

d

fo

r

mula

int

o

le

r

a

n

c

e

,

2

1

4

7

hyp

e

r

t

o

nic

fo

r

mula

s

,

2

1

4

7

la

c

t

o

s

e

-

fr

e

e

fo

r

mula

,

2

1

4

7

ma

n

a

g

e

me

nt

o

f

me

t

a

b

o

lic

e

r

r

o

r

s

,

2

1

4

5

nutr

it

io

n

a

l

a

s

s

e

s

s

me

nt

,

2

1

4

6–

2

1

4

8

p

h

e

ny

la

la

nin

e

-

fr

e

e

th

e

r

a

p

e

ut

ic

fo

r

mula

s

,

2

1

4

5

p

ur

e

c

o

w

’

s

milk

,

2

1

4

5

r

e

a

dy

-

t

o

-

fe

e

d

fo

r

m

fe

e

d

s

,

2

1

4

5

r

o

ut

e

o

f

a

dminis

tr

a

t

io

n

,

2

1

4

6

,

2

1

4

7

t

s

o

lid

fo

o

d

s

,

2

1

4

5

s

o

y

-

b

a

s

e

d

fo

r

mula

s

,

2

1

4

4

th

e

r

a

p

e

ut

ic

fo

r

mula

s

,

2

1

4

5

–

2

1

4

6

init

ia

t

io

n

o

f,

7

7

5

–

7

7

6

int

o

le

r

a

n

c

e

t

o

,

7

8

8

–

7

9

0

me

dic

a

r

e

a

n

d

,

7

8

9

t

me

dic

a

t

io

n

s

a

n

d

,

7

8

5

–

7

9

0

p

a

t

ie

nt

s

e

le

c

t

io

n

a

n

d

r

o

ut

e

o

f

fe

e

din

g

fo

r

,

7

6

8

–

7

7

0

p

r

o

t

e

in

in

,

7

7

8

t

p

ulmo

n

a

r

y

dis

e

a

s

e

a

n

d

,

7

7

9

–

7

8

0

fo

r

r

e

n

a

l

fa

ilur

e

,

7

8

0–

7

8

2

tr

a

n

s

fe

r

t

o

h

o

me

o

n

,

7

8

8

tr

a

n

s

it

io

n

t

o

int

e

r

mitt

e

nt

d

e

liv

e

r

y

o

f,

7

7

6

tub

e

p

la

c

e

me

nt

in

,

7

7

0–

7

7

1

,

7

7

0

t